Skip to main content
NCBI home page
Journal of Diabetes Research logoLink to Journal of Diabetes Research
. 2021 Dec 24;2021:1254968. doi: 10.1155/2021/1254968

Association of CDKAL1 RS10946398 Gene Polymorphism with Susceptibility to Diabetes Mellitus Type 2: A Meta-Analysis

Ning Xu 1, Ting-Ting Zhang 1, Wen-Jia Han 2, Li-Ping Yin 3, Nan-Zheng Ma 4, Xiu-Yan Shi 5,✉, Jiang-Jie Sun 6,✉
PMCID: PMC8719992  PMID: 34977253

Abstract

Background

Diabetes is one of the common chronic diseases in which susceptibility is determined by a combination of genetic and environmental factors, and more than 90% of diabetic patients are diabetes mellitus type 2 (T2DM). The existing studies on the association between CDKAL1 rs10946398 gene polymorphism and susceptibility to type 2 diabetes are inconsistent across populations.

Aim

We aim to explore the association between CDKAL1 rs10946398 gene polymorphism and susceptibility to type 2 diabetes in different populations.

Methods

We examined all studies before June 12, 2021, that associated CDKAL1 rs10946398 with T2DM. Heterogeneity was assessed by meta-analysis of allelic inheritance models (A vs. C), dominant inheritance models (AA vs. AC+CC), and recessive inheritance model (AA+AC vs. CC); I2 was used to assess the heterogeneity (if I2 < 50%, the fixed-effects model was used; if I2 ≥ 50%, the random-effects model was used for data consolidation); correlation was judged by a forest map; potential publication bias was tested by the Egger test (p > 0.05 indicates that there is no publication bias).

Results

Fourteen data totaling 30288 subjects, including 19272 controls and 11016 patients with T2DM, met our inclusion criteria. In the Asian population, the differences were statistically significant (p < 0.01) for dominant genetic model (OR = 0.75, 95%CI = 0.64-0.88, p = 0.0003). But the allelic effect model (OR = 0.87, 95%CI = 0.75-1.02, p = 0.08) and the recessive genetic model (OR = 0.85, 95%CI = 0.66-1.10, p = 0.23) were not statistically significant (p > 0.01). In the non-Asian population, the differences were statistically significant (p < 0.01) for the allelic effect model (OR = 0.83, 95%CI = 0.77-0.88, p < 0.00001), the dominant model (OR = 0.79, 95%CI = 0.72-0.87, p < 0.00001), and the recessive model (OR = 0.78, 95%CI = 0.70-0.87, p < 0.0001).

Conclusion

In this study, CDKAL1 RS10946398 was positively associated with T2DM, but the association was different in Asian populations.

1. Introduction

According to the World Health Organization (WHO), approximately 3.4 million people died from developing diabetes in 2004, and it predicts that the number of diabetes deaths will double between 2005 and 2030. The International Diabetes Federation predicts that the global prevalence of diabetes will reach 642 million cases by 2040 (International Diabetes Federation, 2015), with type 2 diabetes accounting for more than 90% of diabetics [1].

Type 2 diabetes mellitus (T2DM), formerly known as non-insulin-dependent or adult-onset diabetes mellitus, is a type of diabetes mellitus. It is caused by poor insulin action which is the relative lack of insulin in patients, and its susceptibility is determined by both genetic and environmental factors [2]. In the context of increasing morbidity and mortality of T2DM, it is of great significance to study the pathogenesis of T2DM.

Previous studies have shown that China [3–6] and other Populations of Asian countries' CDKAL1 RS10946398 locus mutation was significantly associated with T2DM [1, 7–10]. The United States [11, 12], Russia [13, 14], Mexico [15], and other non-Asian populations of CDKAL1 RS10946398 were also significantly associated with T2DM. It is noteworthy that a variant of the CDKAL1 RS10946398 locus in the population of the Asian country of the United Arab Emirates may not be directly associated with the development of T2DM [1]. These show that CDKAL1 rs10946398 locus variants play different roles in different study populations. Therefore, it is of great significance to study the relationship between CDKAL1 rs10946398 locus variation and T2DM susceptibility in different populations.

1.1. Retrieval Strategy

An advanced search of the literature search library was conducted by using “T2DM CDKAL1” and “CDKAL1 rs10946398” as key to search terms in the China National Knowledge Infrastructure (CNKI), PubMed, and WanFang digital databases, with the last search conducted on June 12, 2021.

1.2. Inclusion and Exclusion Criteria

The following studies were included [16, 17]:

  1. Case-control studies focus on the association between the CDKAL1 rs10946398 polymorphism and T2DM in adults

  2. Patients were randomly selected with no special restrictions on gender, family history, etc.

  3. Studies provide accurate control and case group data sources

  4. The data provided in the study report were statistically significant. The study results had specific OR values, 95% CI

  5. Studies met the diagnostic criteria of T2DM published by the World Health Organization (WHO) in 2019, and the control group all met the law of H-W genetic balance

The following studies were excluded:

  1. There were only case groups or a lack of sufficient controls

  2. Statistical data are erroneous or there are significant differences in the statistics of the same study in different literatures

  3. The overall sample size is insufficient

  4. Literature reviews and case reports were excluded

1.3. Data Extraction

Two investigators independently read the literature and extracted information from the eligible literature based on exclusion and inclusion criteria. In case of ambiguity, a consensus was reached on whether to extract the paper data through discussion with the third investigator. For each paper, the following information was collected: (i) author's name, (ii) year of publication, (iii) ethnicity and country of the study population, (vi) number of included cases and controls, and (vii) genotype data [3]. The literature screening process is shown in Figure 1.

Figure 1.

Figure 1

Open in a new tab

Literature screening flow chart.

1.4. Statistical Methods

Review Manager 5 software was used to complete the meta-analysis. Stata software was used to complete the Egger test.

2. Results

2.1. Baseline Characteristics of Included Studies

We obtained articles on the relationship between CDKAL1 rs10946398 diversity and T2DM susceptibility from PubMed and CNQ. After reading the title, year, author, and abstract of the papers, we conducted the first screening. The second screening was performed by reading the full text and analyzing whether the data was statistically significant. Finally, 14 literatures were included. A total of 14 datasets were obtained for meta-analysis by reading through the full text to filter the data required for recording. A total of 30288 subjects were included in the meta-analysis, including a total of 11016 in the T2DM patient group and 19272 in the control group. Eight of the datasets were from the Asian study population: 3 from China, 1 from India, 1 from Korea, 1 from Japan, 1 from Iran, and 1 from the United Arab Emirates; 6 were from the non-Asian study population: 3 from the USA, 2 from Russia, and 1 from Mexico. Information on the first author, study year, sample size, ethnicity, BMI, mean age of control and case groups, and risk allele frequency for each study is shown in Table 1.

Table 1.

Association of CDKAL11 rs10946398 polymorphism with T2DM susceptibility.

First author Region Race BMI Age (yr) Controls Cases
Controls Cases Controls Cases N AA AC CC A C N AA AC CC A C
Horikoshi (2007) Asian Japanese 23.8 ± 3.7 24.3 ± 3.9 69.5 ± 6.8 63.1 ± 9.5 861 280 423 158 983 739 852 239 434 179 912 792
Joshua P (2008) Non-Asian American NA NA NA NA 1054 184 513 357 881 1227 993 147 470 376 764 1222
Y. Liu (2008) Asian Chinese 24.5 ± 3.2 25.3 ± 3.4 58.1 ± 9 63.8 ± 9 1822 588 862 372 2038 1606 1903 707 903 293 2317 1489
Herder (2008) Non-Asian American 27.7 ± 4.3 30.9 ± 5.0 61.6 ± 9.7 59.9 ± 7.9 1438 705 604 129 2014 862 433 177 200 56 554 312
Eun Seok (2009) Asian South Korea NA NA 37.4 ± 9.3 42.6 ± 9.1 444 134 220 90 488 400 145 31 72 42 134 156
Cheng Hu (2009) Asian Chinese 23.57 ± 3.25 24.04 ± 3.51 57.39 ± 12.37 61.21 ± 12.62 1785 613 866 306 2092 1478 1850 578 912 360 2068 1632
M. Cruz (2010) Non-Asian Mexico 27.50 ± 3.55 29.25 ± 4.76 43.60 ± 6.63 53..44 ± 7.42 548 270 229 49 769 327 519 242 225 52 709 329
Ganesh (2010) Asian India Women 24.90 (21.10–28.60)
Men 23.20 (20.20–25.70)		 Women 26.70 (24.20–29.20)
Men 23.80 (22.00–26.00)		 50 (44–60) 53 (45–62) 1006 628 334 44 1590 422 1020 589 372 59 1550 490
Dimitry A (2011) Non-Asian Russian 26.9 ± 4.8 28.3 ± 5.9 59.9 ± 7.9 26.9 ± 4.8 767 367 330 70 1064 470 769 333 337 99 1003 535
Jessican (2012) Non-Asian American 29.5 ± 7.6 33.7 ± 7.6 48.6 ± 13.0 46.0 ± 12.3 567 105 278 184 488 646 1150 175 547 428 897 1403
Aleksey G Nikitin (2017) Non-Asian Russian 28.7 ± 4.8 30.5 ± 5.0 54.4 ± 11.0 60.0 ± 10.2 443 297 124 22 718 168 862 500 293 69 1293 431
Oswald Ndi Nfor (2018) Asian Taiwanese women NA NA 47.60 ± 10.80 55.56 ± 9.19 8934 3707 4061 1166 11475 6393 974 353 441 180 1147 801
Mariam Al Ali (2019) Asian Emirati NA NA NA NA 264 137 99 28 373 155 153 86 57 10 229 77
Kazem Vatankhah Yazdi (2020) Asian Iranian 23.07 ± 1.03 24.00 ± 1.23 65.5 ± 7.3 65 ± 7.5 106 46 50 10 142 70 162 31 104 27 166 158
Open in a new tab

3. Results of Meta-Analysis

In the evaluation of the relationship between the CDKAL1 rs10946398 gene and T2DM susceptibility, a total of 14 studies were included in the meta-analysis after literature data search, screening, and verification. In order to analyze the association between CDKAL1 rs10946398 polymorphism and susceptibility to T2DM, we analyzed the relationships between A and C alleles, AA+AC and CC genotypes, AA and AC+CC genotypes in T2DM patients and controls. Since 8 studies were from Asia and 6 were from non-Asia, we stratified the Asian and non-Asian populations.

We examined heterogeneity separately for the study populations, using I2, to assess the magnitude of heterogeneity (if I2 < 50%, a fixed-effects model was used; if I2 ≥ 50%, a random-effects model was used to combine the data). Because our data were randomly selected and we wanted to reflect the overall situation with a small sample size, only the allelic genetic model and the recessive genetic model in non-Asian populations show that I2 < 50%, so we used the random-effects model (see Table 2).

Table 2.

Heterogeneity test.

CDKAL1 Group A fixed-effects model A random-efforts model Heterogeneity
OR (95% CI) Z p OR (95% CI) z p X 2 I 2 (%) PQ test
A vs. C Total 0.89 [0.86, 0.92] 6.17 p < 0.00001 0.85 [0.77, 0.94] 3.25 p = 0.001 76.82 83% p < 0.00001
Asian 0.92 [0.88, 0.97] 3.36 p = 0.008 0.87 [0.75, 1.02] 1.73 p = 0.08 65.37 89% p < 0.00001
Non-Asian 0.83 [0.78, 0.88] 5.88 p < 0.00001 0.83 [0.77, 0.88] 5.55 p < 0.00001 5.59 11% p = 0.35
AA vs. AC+CC Total 0.77 [0.73, 0.82] 9.15 p < 0.00001 0.77 [0.70, 0.85] 5.42 p < 0.00001 149.89 92% p < 0.00001
Asian 0.83 [0.77, 0.88] 7.68 p < 0.00001 0.75 [0.64, 0.88] 3.61 p = 0.0003 29.52 76% p = 0.0001
Non-Asian 0.79 [0.72, 0.86] 4.99 p < 0.00001 0.79 [0.72, 0.87] 4.97 p < 0.00001 84.86 96% p = 0.58
AA+AC vs. CC Total 0.86 [0.80, 0.92] 4.47 p < 0.00001 0.81 [0.69, 0.94] 2.68 p = 0.007 33.42 61% p = 0.001
Asian 0.91 [0.83, 0.99] 2.23 p = 0.03 0.85 [0.66, 1.10] 1.21 p = 0.23 59.98 86% p < 0.00001
Non-Asian 0.78 [0.70, 0.87] 4.39 p < 0.0001 0.78 [0.70, 0.87] 4.38 p < 0.0001 1.70 0 p < 0.00001
Open in a new tab

In the total population, the differences were statistically significant (p < 0.01) for the allelic genetic models (OR = 0.85, 95%CI = 0.77-0.94, p = 0.001), the dominant genetic models (OR = 0.77, 95%CI = 0.70-0.85, p < 0.00001), and the recessive genetic models (OR = 0.81, 95%CI = 0.69-0.94, p = 0.007). The results are shown in Figures 2–4.

Figure 2.

Figure 2

Open in a new tab

Forest plot of meta-analysis of the A vs. C allele model associated with T2DM at CDKAL1 rs10946398 locus.

Figure 3.

Figure 3

Open in a new tab

Meta-analysis of a T2DM-associated AA vs. AC+CC genotype model at CDKAL1 RS10946398 locus forest map.

Figure 4.

Figure 4

Open in a new tab

Meta-analysis of a T2DM-associated AA+AC vs. CC genotype model at CDKAL1 RS10946398 locus forest map.

In the Asian population, the differences were statistically significant (p < 0.01) for dominant genetic model (OR = 0.75, 95%CI = 0.64-0.88, p = 0.0003). But the allelic effect model (OR = 0.87, 95%CI = 0.75-1.02, p = 0.08) and the recessive genetic model (OR = 0.85, 95%CI = 0.66-1.10, p = 0.23) were not statistically significant (p > 0.01). The results are shown in Figures 2–4.

In non-Asian populations, the differences were statistically significant (p < 0.01) for the allelic genetic model (OR = 0.83, 95%CI = 0.77-0.88, p < 0.00001), the dominant genetic model (OR = 0.79, 95%CI = 0.72-0.87, p < 0.00001), and the recessive genetic model (OR = 0.78, 95%CI = 0.70-0.87, p < 0.0001). The results are shown in Figures 2–4.

3.1. Publication Bias

We used Stata software for the Egger test, and the p values of allelic inheritance models (A vs. C), recessive inheritance model (AA+AC vs. CC), and dominant inheritance models (AA vs. AC+CC) were 0.114, 0.307, and 0.304, respectively, which were greater than 0.05, indicating that there was no publication bias. What is more, according to the symmetry of the funnel plot, the existence of publication bias can also be judged. The results are shown in Figures 5–7; it can be found that all points in the funnel plot are distributed symmetrically along both sides of the midline, so there is no bias.

Figure 5.

Figure 5

Open in a new tab

A vs. C allelic funnel plot.

Figure 6.

Figure 6

Open in a new tab

AA vs. AC+CC genotype funnel plot.

Figure 7.

Figure 7

Open in a new tab

AA+AC vs. CC genotype funnel plot.

4. Discussion

According to a large number of genome-wide association analyses (GWAS), CDK5 regulation-related protein 1-LIAK 1 (CDKAL1) gene under the action of high glucose toxicity will increase the body's demand for insulin, and pancreatic β cells continue to be activated, which may inhibit the activity of CDK5 in pancreatic β cells. Insulin secretion is reduced by lowering the expression of insulin genes [18, 19]. Because mutations in CDKAL1 may lead to impaired insulin secretion, thus, it increases the risk of T2DM, and CDK5 regulates the related protein 1-LIAK 1 (CDKAL1) gene which is one of the most repeatable risk genes in T2DM [20]. In particular, SNPs rs10946398 and rs7754840 of CDKAL1 have the strongest correlation with T2DM [20].

To study the relationship between the variation of CDKAL1 RS10946398 locus and the susceptibility to T2DM in different populations, 14 sets of data were finally used for meta-analysis through data investigation and screening, and 13 sets of data showed that the CDKAL1 RS10946398 locus was significantly correlated with the incidence of T2DM; for example, a study by Nfor et al. showed a significant association between CDKAL1 RS10946398 and T2DM in Taiwanese. CC carriers were more associated with T2DM than AC carriers, and C allele carriers were more associated with type 2 diabetes than A allele carriers [6]. A study by Herder et al. found that CDKAL1rs10946398 was significantly associated with impaired glucose metabolism or β cell function. CDKAL1rs10946398 also plays an important role in the pathogenesis of T2DM in the detected Russian population [12]. Only one set of data showed that CDKAL1 RS10946398 locus was not significantly associated with the pathogenesis of T2DM. The study by Al Ali et al. showed that the CDKAL1 RS9939609 variant in the United Arab Emirates population may not be directly related to the development of T2DM [1]. Therefore, the role of CDKAL1 rs10946398 locus variation in different study populations is different.

In this study, a meta-analysis of the included 14 groups of data concerning the CDKAL1 rs10946398 locus and T2DM was performed by analyzing allelic models (A vs. C), recessive genetic models (AA+AC vs. CC), and dominant genetic models (AA vs. AC+CC) in T2DM patients and controls. Of the 30288 subjects, including 19272 controls and 11016 T2DM patients, we found that CDKAL1 RS10946398 gene polymorphism locus is associated with type 2 diabetes mellitus in different ethnic groups, and the degree of correlation is different in different genetic models.

In the Asian population, the differences were statistically significant (p < 0.01) for the dominant genetic model (OR = 0.75, 95%CI = 0.64-0.88, p = 0.0003). But the allelic effect model (OR = 0.87, 95%CI = 0.75-1.02, p = 0.08) and the recessive genetic model (OR = 0.85, 95%CI = 0.66-1.10, p = 0.23) were not statistically significant (p > 0.01). The risk ratio of the A allele was higher than that of the C allele. In the non-Asian population, the differences were statistically significant (p < 0.01) for the allelic effect model (OR = 0.83, 95%CI = 0.77-0.88, p < 0.00001), the dominant model (OR = 0.79, 95%CI = 0.72-0.87, p < 0.00001), and the recessive model (OR = 0.78, 95%CI = 0.70-0.87, p < 0.0001). The risk ratio of the A allele was higher than that of the C allele [21].

We used 14 sets of data for meta-analysis of the locus genetic model (A vs. C) recessive models (AA+AC vs. CC) and dominant models (AA vs. AC+CC). Except for the Asian allelic effect model and recessive gene model (p > 0.01), other models were statistically significant (p < 0.01). CDKAL1rs10946398 could significantly increase the risk of T2DM in the allele model of Asian and in all models of non-Asian. But this result cannot be attributed to differences in ethnicity; it could also be due to the small sample size. In conclusion, the CDKAL1 rs10946398 gene variant may increase the susceptibility to T2DM.

Acknowledgments

This work was supported in part by the Nanjing Project of Medical Science and Technology Development (No. YKK17207), Scientific Research Project of Nanjing Science and Technology Development Plan (No. 201803041), Natural Science Foundation of Anhui Province of China (No. 1908085MG233), Quality Engineering for research projects of the Anhui Department of Education (Nos. 2020SJJXSFK1341 and 2020wyxm108), and the Natural Science Foundation for the Higher Education Institutions of Anhui Province of China (No. KJ2019A0945).

Contributor Information

Xiu-Yan Shi, Email: wood20040@126.com.

Jiang-Jie Sun, Email: sunjiangjie@ahmu.edu.cn.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors' Contributions

NX and TZ designed this study. NX and TZ searched databases and collected full-text papers. NX, WH, and JD extracted and analyzed data. JS provided guidance for statistical analysis. NX wrote the manuscript. NX, LY, NM, XS, and TZ reviewed the manuscript. JS and XS have provided financial support for this work. NX and TZ contributed equally to this work.

References

  • 1.al Ali M., el hajj Chehadeh S., Osman W., et al. Investigating the association of rs7903146 of TCF7L2 gene, rs5219 of KCNJ11 gene, rs10946398 of CDKAL1 gene, and rs9939609 of FTO gene with type 2 diabetes mellitus in Emirati population. Meta Gene . 2019;21(9, article 100600) doi: 10.1016/j.mgene.2019.100600. [DOI] [Google Scholar]
  • 2.Malecki M. Genetics of type 2 diabetes mellitus. Diabetes Research and Clinical Practice . 2005;68(3):S10–S21. doi: 10.1016/j.diabres.2005.03.003. [DOI] [PubMed] [Google Scholar]
  • 3.Liu Y., Yu L., Zhang D., et al. positive association between variations in CDKAL1 and type 2 diabetes in Han Chinese individuals. Diabetologia . 2008;51(11):2134–2137. doi: 10.1007/s00125-008-1141-6. [DOI] [PubMed] [Google Scholar]
  • 4.Hu C., Zhang R., Wang C., et al. PPARG, KCNJ11, CDKAL1, CDKN2A-CDKN2B, IDE-KIF11-HHEX, IGF2BP2 and SLC30A8 are associated with type 2 diabetes in a Chinese population. PLoS One . 2009;4(10):1–6. doi: 10.1371/journal.pone.0007643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Lin Y., Li P., Cai L., et al. Association study of genetic variants in eight genes/loci with type 2 diabetes in a Han Chinese population. BMC Medical Genetics . 2010;11(1):1–8. doi: 10.1186/1471-2350-11-97. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Nfor O. N., Wu M. F., Lee C. T., et al. Body mass index modulates the association between CDKAL1 rs10946398 variant and type 2 diabetes among Taiwanese women. Scientific Reports . 2018;8(1):1–8. doi: 10.1038/s41598-018-31415-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Vatankhah Yazdi K., Kalantar S. M., Houshmand M., et al. SLC30A8, CDKAL1, TCF7L2, KCNQ1 and IGF2BP2 are associated with type 2 diabetes mellitus in Iranian Patients. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy . 2020;13(3):897–906. doi: 10.2147/DMSO.S225968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Kang E. S., Kim M. S., Kim C. H., et al. Association of common type 2 diabetes risk gene variants and posttransplantation diabetes mellitus in renal allograft recipients in Korea. Transplantation . 2009;88(5):693–698. doi: 10.1097/TP.0b013e3181b29c41. [DOI] [PubMed] [Google Scholar]
  • 9.Horikoshi M., Hara K., Ito C., et al. Variations in the HHEX gene are associated with increased risk of type 2 diabetes in the Japanese population. Diabetologia . 2007;50(12):2461–2466. doi: 10.1007/s00125-007-0827-5. [DOI] [PubMed] [Google Scholar]
  • 10.Chauhan G., Spurgeon C. J., Tabassum R., et al. Impact of common variants ofPPARG,KCNJ11,TCF7L2,SLC30A8,HHEX,CDKN2A,IGF2BP2, andCDKAL1on the risk of type 2 diabetes in 5,164 Indians. Diabetes . 2010;59(8):2068–2074. doi: 10.2337/db09-1386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Lewis J. P., Palmer N. D., Hicks P. J., et al. Association analysis in African Americans of European-derived type 2 diabetes single nucleotide polymorphisms from whole-genome association studies. Diabetes . 2008;57(8):2220–2225. doi: 10.2337/db07-1319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Herder C., Rathmann W., Strassburger K., et al. Variants of thePPARG,IGF2BP2,CDKAL1,HHEX, andTCF7L2Genes confer risk of type 2 diabetes independently of BMI in the German KORA studies. Hormone and Metabolic Research . 2008;40(10):722–726. doi: 10.1055/s-2008-1078730. [DOI] [PubMed] [Google Scholar]
  • 13.Chistiakov D. A., Potapov V. A., Smetanina S. A., Bel’chikova L. N., Suplotova L. A., Nosikov V. V. The carriage of risk variants of CDKAL1 impairs beta-cell function in both diabetic and non-diabetic patients and reduces response to non-sulfonylurea and sulfonylurea agonists of the pancreatic KATP channel. Acta Diabetologica . 2011;48(3):227–235. doi: 10.1007/s00592-011-0299-4. [DOI] [PubMed] [Google Scholar]
  • 14.Nikitin A. G., Potapov V. Y., Brovkina O. I., et al. Association of polymorphic markers of genesFTO,KCNJ11, CDKAL1, SLC30A8,andCDKN2Bwith type 2 diabetes mellitus in the Russian population. Peer J . 2017;5(9, article e3414) doi: 10.7717/peerj.3414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Cruz M., Valladares-Salgado J., Garcia-Mena J., et al. Candidate gene association study conditioning on individual ancestry in patients with type 2 diabetes and metabolic syndrome from Mexico City. Diabetes/Metabolism Research and Reviews . 2010;26(4):261–270. doi: 10.1002/dmrr.1082. [DOI] [PubMed] [Google Scholar]
  • 16.Liu X., Liang J., Geng H., Xu W., Teng F., Yang M. Association of the CDKAL1 polymorphism rs10946398 with type 2 diabetes mellitus in adults. Medicine . 2020;99(30):e21383–e21388. doi: 10.1097/MD.0000000000021383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Dehwah M. A. S., Wang M., Huang Q.-Y. CDKAL1 and type 2 diabetes: a global meta-analysis. Genetics and Molecular Research . 2010;9(2):1109–1120. doi: 10.4238/vol9-2gmr802. [DOI] [PubMed] [Google Scholar]
  • 18.Lyssenko V., Jonsson A., Almgren P., et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. The New England Journal of Medicine . 2008;359(21):2220–2232. doi: 10.1056/NEJMoa0801869. [DOI] [PubMed] [Google Scholar]
  • 19.Groenewoud M. J., Dekker J. M., Fritsche A., et al. Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps. Diabetologia . 2008;51(9):1659–1663. doi: 10.1007/s00125-008-1083-z. [DOI] [PubMed] [Google Scholar]
  • 20.Wei F. Y., Tomizawa K. Functional loss of Cdkal1, a novel tRNA modification enzyme, causes the development of type 2 diabetes [review] Endocrine Journal . 2011;58(10):819–825. doi: 10.1507/endocrj.EJ11-0099. [DOI] [PubMed] [Google Scholar]
  • 21.Muhadasi T., Patamu M., Tuolanguli M. Association of CDKAL1 rs10946398 C/A polymorphism with type 2 diabetes. Journal of Shandong University (Health Sciences) . 2016;54(2):75–85. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The data used to support the findings of this study are included within the article.

Articles from Journal of Diabetes Research are provided here courtesy of Wiley

RESOURCES